Update on Joy 10/27
 

Hi everyone, this is Joy's sister. I just wanted to give a quick update on Joy and maybe get some advice. She has been taken off the Ixempra due to rising markers and severe neuropathy. Her oncologist is starting her on Doxil/cytotoxin and Herceptin tomorrow. Her thinking is that she has had good response to anthracyclines (sp?) before, she did well on epirubicin. She had talked about doing Herc. and Avastin last week but now she has changed her mind, she says because there is more than 50% liver involvement, she feels like Avastin may actually make things worse?? Also, she's not sure if her insurance would pay for it. It seems like on this board, BC Mets and YSC there are a lot of women on Avastin, and not many complaints about insurance problems. We are curious to get any of your thoughts about this treatment, Avastin and other treatment ideas. We feel like we are running out of options. Any thoughts would be appreciated. And as always we are thinking of all of you! Thanks you so much and take care, Jennifer

Re: Update on Joy 10/27
 

Jennifer ~
Thank you for visiting us and giving us a little update on Joy. I confess I always check every week to see if something is written about her. I don't have any personal advice for your questions but I am sure that you will get lots of fantastic advice or ideas here. These folks amaze me on the knowledge they have!
Please give Joy my love and that I wrap my cyber arms around her.
Ruth

Re: Update on Joy 10/27
 

Nothing to add but thoughts and prayers for you and Joy---

Re: Update on Joy 10/27
 

Sounds like a good try for treatment for Joy. Wish I really knew something to suggest. Please tell Joy she's terrific and I send prayers and love, ma

Re: Update on Joy 10/27
 

Not that many postings about Avastin are found on this board by using the 'Search' function. Here's some information provided by WebMd last year when it was first approved for breast cancer treatment:

Avastin for Breast Cancer Treatment

The cancer drug was recently approved to treat metastatic breast cancer, but there are still questions about Avastin that need to be answered.
By Gina Shaw
WebMD Feature
Reviewed by Matthew Hoffman, MD



In February 2008, the FDA approved a new drug, Avastin, for the treatment of breast cancer that has metastasized. Cancer that has metastasized has spread to other organs such as the lungs, liver, or bones. This decision to approve Avastin was somewhat surprising. In December, an FDA advisory committee had recommended that the FDA not approve the drug. The vote, though was close -- 5 to 4.
What is Avastin? And what can it do for some women with breast cancer?
Avastin is one of a newer group of medications called anti-angiogenesis drugs or angiogenesis inhibitors. They work by choking off blood supply to tumors. This prevents the tumors from forming new blood vessels and cuts off their growth. Avastin had already been approved for use in treating colorectal cancer and lung cancer.
In women with metastatic breast cancer, a large clinical trial showed that Avastin both shrank existing tumors and lengthened what's called "progression-free survival." That's the time it takes for the disease to worsen. In the study, women who took Avastin in combination with the standard drug Taxol survived almost twice as long without their disease worsening as did women taking Taxol alone. That was an average of 11.3 months compared with 5.8 months. Tumors also shrank more in patients taking Avastin than in those taking Taxol alone. Another trial, released in June 2008, found similar results.
But there was no difference in what both oncologists and women with breast cancer see as most important: overall survival. Women taking Avastin did not live any longer than those only taking Taxol. That's why the FDA's decision in February was a bit of a surprise.
"As much as we try to be driven by science and evidence, if there's any possible advantage that can be given to the patient, we want to do it," says Yelena Novik, MD. Novik is medical director of the clinical trials office of the New York University Clinical Cancer Center at NYU Cancer Institute.
Avastin: Quality of Life vs. Quantity of Life

Avastin can be an important drug for many women with metastatic breast cancer, says Eric Weiner. Weiner directs the breast oncology center at the Gillette Center for Women's Cancers at the Dana-Farber Cancer Institute in Boston. "The fact of the matter is that progression-free survival can be important for patients," he says. "Living with cancer under control is obviously a good thing. That is it's good if you can do it without paying too much of a price in terms of side effects from the treatment."
Side effects are a concern with Avastin. They can include:

• High blood pressure
• Blood clots
• Heart problems
• Bowel perforation
• Proteinuria (excess protein in the urine, which can signal kidney damage)

"These are clear-cut issues which may also contribute to poor outcomes for some patients," says Novik. "We particularly have to be concerned about the risk of thromboembolic events -- a stroke. This is rare, but it's a significant concern."
But Avastin's side-effect profile still compares favorably to many chemotherapy drugs. And for many women, the drug is well tolerated, says Lillie Shockney, RN. Shockney is administrative director of the Johns Hopkins Breast Center. "Women with metastatic disease are concerned about having quality of life and quantity of life at the same time. I'm working with a patient right now who's on Avastin. She's able to continue working, which is a real relief since she's a single woman and lives alone and needs to support herself for as long as she can. Some treatments can really beat you up, and you aren't able to be productive outside your home."

What the Future Holds for Avastin and Breast Cancer Treatment

With Avastin, there are no known predictors of a better or worse response to the drug. "If we could identify what sets apart the responders to Avastin, then those people who respond might, in fact, demonstrate a pretty clear survival advantage," says Weiner. "What we really need are better predictors of both toxicity and efficacy."
But such biomarkers for Avastin, unlike Herceptin, a drug that was approved in 2005 for the treatment of certain early-stage breast cancers, have not yet been identified. In the meantime, doctors at leading institutions like Dana-Farber, NYU, and Johns Hopkins are prescribing Avastin to many of their patients with metastatic breast cancer. When they do, it's usually in combination with Taxol -- the way it was in the clinical trials.
"Not every woman will receive Avastin," says Weiner. "For example, if I want to give a drug like capecitabine, which unlike Taxol does not involve hair loss, then I would not give Avastin with it. That's because studies have not shown any advantages. But many women in our institution will receive chemotherapy plus Avastin."
A large trial is also now evaluating Avastin as a treatment for early-stage breast cancer. It has recruited some 1,800 of the nearly 5,000 patients it needs. The trial will compare Avastin to a placebo in combination with a current standard chemotherapy for early-stage breast cancer. The results are not expected for several years.

"We're still pondering how best to use Avastin," Novik says, "and we don't have all the answers."

Re: Update on Joy 10/27
 

Can Lapatinib be included for "total her2 blockade"?
Could she get Zoledronic Acid (Zometa) dose 24 hrs after her Doxil? It is thought to increase effect of Doxorubuicin.

Re: Update on Joy 10/27
 

My onc. has said that doxil and herceptin shouldn't be given together because of potential cardiac issues. Ask Joy's onc. about that. Thank you for the update on Joy and please tell her she's in my thoughts. I hope the switch in meds will get her feeling stronger with less side effects soon.

Re: Update on Joy 10/27
 

Jennifer,

Thanks for letting us know how Joy is. Hope she can come to the board herself soon.

Amelia

Re: Update on Joy 10/27
 

Thanks so much for the update! I do not have any advice or experience to share, so will send along prayers!! Joy has been an integral part of this board for me and I wish her nothing but the best!!! xo Suzan

Re: Update on Joy 10/27
 

Hi Jennifer and Joy! Just wanted to send a prayer and a cheer to ya! Have you decided on a treatment and is Joy doing better?
Lots of love and positive thoughts, ma

Re: Update on Joy 10/27
 

Re: Update on Joy 10/27
 

I am so glad to hear they are considering her for Avastin. I was going to start Avastin/Ixempra before I became aware of the p53 gene therapy for Li-Fraumeni Syndrome (which I am positive for). So I put everything off, to wait for the 4 week cleansing to start the trial, and the crap moved into my brain. Now I am starting WBR till Nov 20th and hopefully start the trial on Nov 30th. Being that it's brand new, I am pretty scared and excited about it - sounding like it's the perfect solution to a 25 year piece of critical research in the genetic problem I have had all my life, and the life of my family. They have tried to deliver it all sorts of ways, but this way sounds like it will finally work.

Back to the subject, Avastin is one of the drugs my oncologist worked with in breast cancer patient trials and said that he felt it was WAY underutilized in the HER2+ metastatic situation, where tumors were VERY knowingly vascular. He said you should be able to just look at the CT and MRI and see that your disease is very vascular. When you get to the point where Tykerb and Herceptin seem to stop working, some of the older therapies stopped working, and you have limited options left - try Avastin. That is my next line, if I don't get into the p53 trial for some unfortunate circumstance.

Re: Update on Joy 10/27
 

Thanks for the update. Adding my prayers to the rest so together we can knock out this crappy disease.